Insider Selling: United Therapeutics Co. (NASDAQ:UTHR) EVP Sells 7,700 Shares of Stock

United Therapeutics Co. (NASDAQ:UTHR) EVP Paul A. Mahon sold 7,700 shares of the business’s stock in a transaction on Thursday, November 21st. The shares were sold at an average price of $367.36, for a total transaction of $2,828,672.00. Following the transaction, the executive vice president now owns 36,710 shares of the company’s stock, valued at $13,485,785.60. This trade represents a 17.34 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

United Therapeutics Price Performance

UTHR stock traded up $5.53 on Friday, reaching $372.89. 257,221 shares of the company traded hands, compared to its average volume of 458,981. The firm has a fifty day simple moving average of $365.06 and a 200-day simple moving average of $331.37. The company has a market cap of $16.65 billion, a P/E ratio of 16.38, a price-to-earnings-growth ratio of 1.05 and a beta of 0.56. United Therapeutics Co. has a one year low of $208.62 and a one year high of $417.82.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.16 by $0.23. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm had revenue of $748.90 million during the quarter, compared to analyst estimates of $722.62 million. During the same quarter in the previous year, the firm earned $5.38 EPS. United Therapeutics’s quarterly revenue was up 22.9% compared to the same quarter last year. On average, sell-side analysts forecast that United Therapeutics Co. will post 25.1 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Tri Ri Asset Management Corp bought a new position in shares of United Therapeutics during the third quarter valued at $7,686,000. TD Private Client Wealth LLC raised its position in United Therapeutics by 10.8% in the 3rd quarter. TD Private Client Wealth LLC now owns 3,688 shares of the biotechnology company’s stock worth $1,322,000 after buying an additional 358 shares during the last quarter. Toronto Dominion Bank lifted its stake in United Therapeutics by 22.6% during the 3rd quarter. Toronto Dominion Bank now owns 5,546 shares of the biotechnology company’s stock valued at $1,987,000 after acquiring an additional 1,021 shares during the period. Chiron Investment Management LLC purchased a new stake in shares of United Therapeutics during the 3rd quarter valued at about $391,000. Finally, Coldstream Capital Management Inc. grew its stake in shares of United Therapeutics by 3.8% in the third quarter. Coldstream Capital Management Inc. now owns 2,166 shares of the biotechnology company’s stock worth $779,000 after acquiring an additional 79 shares during the period. Institutional investors own 94.08% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on UTHR shares. The Goldman Sachs Group increased their price objective on United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a research report on Friday, November 1st. Bank of America lowered their target price on United Therapeutics from $303.00 to $280.00 and set an “underperform” rating for the company in a research note on Thursday, August 1st. Jefferies Financial Group raised their price target on United Therapeutics from $315.00 to $432.00 and gave the stock a “buy” rating in a research report on Monday, September 23rd. LADENBURG THALM/SH SH boosted their price objective on United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. Finally, Wells Fargo & Company increased their price objective on United Therapeutics from $350.00 to $380.00 and gave the company an “overweight” rating in a research note on Tuesday, August 20th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $370.86.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.